^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    BRAF exon 11 mutation

    i
    Other names: BRAF, B-raf proto-oncogene, B-raf proto-oncogene, Serine/threonine kinase, V-Raf murine sarcoma viral oncogene homolog B, Serine/threonine-protein kinase B-Raf, Proto-oncogene B-Raf, BRAF1, RAFB1, B-raf proto-oncogene Serine/threonine-protein kinase, Murine sarcoma viral (V-Raf) oncogene homolog B1, B-raf serine/threonine-protein, 94 KDa B-raf protein, B-RAF1
    Entrez ID:
    673
    Related biomarkers:
    Expression
    Mutation
    CNA
    Fusion
    Others
    Associations

    News

    Trials
    2ms
    Cross-Species Comparison of the Pan-RAF Inhibitor LY3009120's Anti-Tumor Effects in Equine, Canine, and Human Malignant Melanoma Cell Lines. (PubMed, Genes (Basel))
    The anti-tumor effects of LY3009120 were observed in nine melanoma cell lines, indicating the potential feasibility of experimental trials with LY3009120. The present study reveals that the irradiation-resistant canine metastasis cells (cRGO1.2) harboring the NRAS p.G13R mutation are significantly LY3009120-sensitive, while the equine metastases-derived eRGO6 cells show significant resistance to LY3009120, which make them both valuable tools for studying resistance mechanisms in comparative oncology.
    Preclinical • Journal
    |
    KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene) • NRAS (Neuroblastoma RAS viral oncogene homolog)
    |
    KRAS mutation • BRAF mutation • NRAS mutation • KIT exon 11 mutation • NRAS Q61 • KRAS Q61H • KRAS exon 2 mutation • NRAS G13 • NRAS G13R • BRAF exon 11 mutation • BRAF exon 15 mutation
    |
    LY3009120
    3ms
    Clinical Trial of Phenformin in Combination With BRAF Inhibitor + MEK Inhibitor for Patients With BRAF-mutated Melanoma (clinicaltrials.gov)
    P1; Trial completion date: Jan 2024 --> Jan 2025 | Trial primary completion date: Jan 2024 --> Jan 2025
    Combination therapy • Trial completion date • Trial primary completion date
    |
    BRAF V600E • BRAF V600 • BRAF V600K • BRAF V600E + BRAF V600K • BRAF exon 11 mutation • BRAF exon 15 mutation
    |
    MSK-IMPACT
    |
    Mekinist (trametinib) • Tafinlar (dabrafenib) • phenformin
    1year
    Paired Comparison of Routine Molecular Screening of Patient Samples with Advanced Non-Small Cell Lung Cancer in Circulating Cell-Free DNA Using Three Targeted Assays. (PubMed, Cancers (Basel))
    "The Plasma-SeqSensei™ SOLID CANCER IVD kit resulted in de novo detection of targetable oncogenic drivers and resistance alterations, with a high sensitivity and accuracy for low and high cfDNA inputs. Thus, this assay is a sensitive, robust, and accurate test."
    Journal
    |
    EGFR (Epidermal growth factor receptor) • KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene) • PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha)
    |
    EGFR mutation • EGFR exon 19 deletion • EGFR exon 20 mutation • KRAS exon 2 mutation • BRAF exon 11 mutation • BRAF exon 15 mutation
    |
    OncoBEAM EGFR v2 Kit • Plasma-SeqSensei™ Solid Cancer IVD Kit
    almost2years
    Clinical Trial of Phenformin in Combination With BRAF Inhibitor + MEK Inhibitor for Patients With BRAF-mutated Melanoma (clinicaltrials.gov)
    P1; Recruiting --> Active, not recruiting | N=40 --> 18
    Combination therapy • Enrollment change • Enrollment closed
    |
    BRAF V600E • BRAF V600 • BRAF V600K • BRAF exon 11 mutation • BRAF exon 15 mutation
    |
    MSK-IMPACT
    |
    Mekinist (trametinib) • Tafinlar (dabrafenib) • phenformin
    2years
    Clinical Trial of Phenformin in Combination With BRAF Inhibitor + MEK Inhibitor for Patients With BRAF-mutated Melanoma (clinicaltrials.gov)
    P1; Trial completion date: Jan 2023 --> Jan 2024 | Trial primary completion date: Jan 2023 --> Jan 2024
    Combination therapy • Trial completion date • Trial primary completion date
    |
    BRAF V600E • BRAF V600 • BRAF V600K • BRAF exon 11 mutation • BRAF exon 15 mutation
    |
    MSK-IMPACT
    |
    Mekinist (trametinib) • Tafinlar (dabrafenib) • phenformin
    2years
    Gene mutations and clinical prognosis of mucosal melanoma in different locations of head and neck. (PubMed, Acta Otolaryngol)
    Gene phenotypes of mucosal melanoma in different locations has differences. Lesions in the nasal cavity and paranasal sinus should be assessed separately from other parts such as the nasopharynx.
    Clinical • Journal
    |
    BRAF (B-raf proto-oncogene) • NRAS (Neuroblastoma RAS viral oncogene homolog) • KIT (KIT proto-oncogene, receptor tyrosine kinase) • PDGFRA (Platelet Derived Growth Factor Receptor Alpha)
    |
    BRAF mutation • NRAS mutation • KIT mutation • KIT exon 11 mutation • KIT exon 9 mutation • PDGFRA mutation • KIT exon 13 mutation • KIT exon 17 mutation • BRAF exon 11 mutation • BRAF exon 15 mutation
    over3years
    Clinical Trial of Phenformin in Combination With BRAF Inhibitor + MEK Inhibitor for Patients With BRAF-mutated Melanoma (clinicaltrials.gov)
    P1, N=40, Recruiting, Memorial Sloan Kettering Cancer Center | Trial completion date: Jan 2021 --> Jan 2023 | Trial primary completion date: Jan 2021 --> Jan 2023
    Trial completion date • Trial primary completion date • Combination therapy
    |
    BRAF V600E • BRAF V600 • BRAF V600K • BRAF exon 11 mutation • BRAF exon 15 mutation
    |
    MSK-IMPACT
    |
    Mekinist (trametinib) • Tafinlar (dabrafenib) • phenformin
    almost4years
    BRAF exon 11 mutant melanoma and sensitivity to BRAF/MEK inhibition: Two case reports. (PubMed, Eur J Cancer)
    No abstract available
    Clinical • Journal
    |
    BRAF (B-raf proto-oncogene)
    |
    BRAF mutation • BRAF exon 11 mutation